Post Market Clinical Follow-up of EUROSCUP Fixe Acetabular Cup
2 other identifiers
observational
120
1 country
4
Brief Summary
EUROSCUP Fixe is intended for use in primary and revision total hip replacement surgery. Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. As part of post market vigilance, EUROS will collect data on EUROSCUP Fixe performances and safety
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2021
Longer than P75 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 27, 2021
CompletedFirst Submitted
Initial submission to the registry
November 24, 2021
CompletedFirst Posted
Study publicly available on registry
December 2, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 29, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2032
ExpectedFebruary 20, 2024
February 1, 2024
9 months
November 24, 2021
February 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Safety of EUROSCUP Fixe
Collect the safety of the device trought complications occurence rate
1 year
Secondary Outcomes (3)
Clinical performances of EUROSCUP Fixe
1 year
Radiological performances of EUROSCUP Fixe
1 year
Survival of EUROSCUP Fixe
10 years
Study Arms (1)
EUROSCUP Fixe
120 patients who received EUROSCUP Fixe
Interventions
Eligibility Criteria
Patient who fulfill the criteria of eligilibilty according to the instructions for use of EUROSCUP Fixe
You may qualify if:
- Patient who received EUROSCUP Fixe.
- Patient informed of its participation to the study
- Patient aged between 18 and 80 years old (\<80).
You may not qualify if:
- Patient presenting a contraindication to EUROSCUP Fixe implantation.
- Patient who refused to participate to the study
- Vulnerable subjects
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- EUROSlead
Study Sites (4)
Clinique Esquirol Saint Hilaire
Agen, 47000, France
Clinique de L'Atlantique
Puilboreau, 17138, France
Centre Hospitalier SECLIN
Seclin, 59113, France
Clinique St Roch
Toulon, 83000, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 24, 2021
First Posted
December 2, 2021
Study Start
October 27, 2021
Primary Completion
July 29, 2022
Study Completion (Estimated)
July 1, 2032
Last Updated
February 20, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share